1. Home
  2. CINGW vs CNF Comparison

CINGW vs CNF Comparison

Compare CINGW & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CNF
  • Stock Information
  • Founded
  • CINGW N/A
  • CNF 1999
  • Country
  • CINGW United States
  • CNF China
  • Employees
  • CINGW 13
  • CNF N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CNF Finance: Consumer Services
  • Sector
  • CINGW Health Care
  • CNF Finance
  • Exchange
  • CINGW Nasdaq
  • CNF Nasdaq
  • Market Cap
  • CINGW N/A
  • CNF N/A
  • IPO Year
  • CINGW 2021
  • CNF 2018
  • Fundamental
  • Price
  • CINGW $0.04
  • CNF $0.70
  • Analyst Decision
  • CINGW
  • CNF
  • Analyst Count
  • CINGW 0
  • CNF 0
  • Target Price
  • CINGW N/A
  • CNF N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • CNF 34.0K
  • Earning Date
  • CINGW N/A
  • CNF 04-29-2025
  • Dividend Yield
  • CINGW N/A
  • CNF N/A
  • EPS Growth
  • CINGW N/A
  • CNF N/A
  • EPS
  • CINGW N/A
  • CNF 0.24
  • Revenue
  • CINGW N/A
  • CNF $109,788,152.00
  • Revenue This Year
  • CINGW N/A
  • CNF $130.65
  • Revenue Next Year
  • CINGW N/A
  • CNF $13.09
  • P/E Ratio
  • CINGW N/A
  • CNF $2.93
  • Revenue Growth
  • CINGW N/A
  • CNF 12.99
  • 52 Week Low
  • CINGW N/A
  • CNF $0.60
  • 52 Week High
  • CINGW N/A
  • CNF $2.84
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CNF 35.67
  • Support Level
  • CINGW N/A
  • CNF $0.71
  • Resistance Level
  • CINGW N/A
  • CNF $0.75
  • Average True Range (ATR)
  • CINGW 0.00
  • CNF 0.05
  • MACD
  • CINGW 0.00
  • CNF 0.01
  • Stochastic Oscillator
  • CINGW 0.00
  • CNF 26.67

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: